Literature DB >> 7541865

Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent.

G Aus1, J Hugosson, L Norlén.   

Abstract

PURPOSE: We investigate the ultimate need for palliative treatments and hospital care in prostate cancer patients treated with noncurative intent.
MATERIALS AND METHODS: A retrospective analysis was done of 514 prostate cancer patients who died between 1988 and 1990.
RESULTS: Of the patients who later died of prostate cancer 61% needed 1 or more palliative treatments (transurethral resection of the prostate, radiation treatment or upper urinary tract diversion) before death. An average of 5 weeks was spent in the hospital due to prostate cancer.
CONCLUSIONS: Patients who failed deferred treatment (thus dying of prostate cancer) needed a considerable amount of hospital care and palliative therapy before they ultimately died of the disease.

Entities:  

Mesh:

Year:  1995        PMID: 7541865     DOI: 10.1097/00005392-199508000-00034

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

Review 1.  Localized prostate cancer: early intervention or expectant therapy?

Authors:  T R Griffiths; D E Neal
Journal:  J R Soc Med       Date:  1997-12       Impact factor: 5.344

Review 2.  [Node-positive prostate cancer. Value of radical prostatectomy].

Authors:  A Heidenreich; A J Schrader
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

3.  The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

4.  [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].

Authors:  A Heidenreich; D Pfister; B Brehmer; D Porres
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

5.  [The role of surgery in locally advanced prostate cancer].

Authors:  R-J Palisaar; J Noldus
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

Review 6.  [Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits].

Authors:  A Heidenreich; D Pfister; D Porres
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

7.  Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Authors:  Ana M Aparicio; Andrea L Harzstark; Paul G Corn; Sijin Wen; John C Araujo; Shi-Ming Tu; Lance C Pagliaro; Jeri Kim; Randall E Millikan; Charles Ryan; Nizar M Tannir; Amado J Zurita; Paul Mathew; Wadih Arap; Patricia Troncoso; Peter F Thall; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2013-05-06       Impact factor: 12.531

8.  Analysis of urological procedures in men who died from prostate cancer using a population-based approach.

Authors:  Kara Babaian; Matthew Truong; Jeremy Cetnar; Deanna S Cross; Fangfang Shi; Mark A Ritter; David F Jarrard
Journal:  BJU Int       Date:  2012-11-06       Impact factor: 5.588

9.  MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes.

Authors:  Ronaldo Hueb Baroni
Journal:  Int Braz J Urol       Date:  2016 Nov-Dec       Impact factor: 1.541

10.  Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.

Authors:  James A Eastham; Michael W Kattan; Paul Fearn; Gabrielle Fisher; Daniel M Berney; Tim Oliver; Christopher S Foster; Henrik Møller; Victor Reuter; Jack Cuzick; Peter Scardino
Journal:  Eur Urol       Date:  2007-05-30       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.